Compare
Abbott Laboratories vs Bristol Myers Squibb Co vs AbbVie Inc. vs Eli Lilly & Co
| Latest fiscal year | Abbott Laboratories ABT | Bristol Myers Squibb Co BMY | AbbVie Inc. ABBV | Eli Lilly & Co LLY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $44.33B | $48.19B | $61.16B | $65.18B |
| Revenue growth (YoY) | +5.7% | -0.2% | +8.6% | +44.7% |
| Gross margin | 56.4% (computed) | n/a | 70.2% (computed) | 83.0% (computed) |
| Operating margin | 18.2% | n/a | 24.6% | n/a |
| Net margin | 14.7% | 14.6% | 6.9% | 31.7% |
| Net income | $6.52B | $7.05B | $4.23B | $20.64B |
| EPS (Diluted) | $3.72 | $3.46 | $2.36 | $22.95 |
| Operating cash flow | $9.57B | $14.16B | $19.03B | $16.81B |
| Free cash flow | $7.39B | $12.85B | $17.82B | n/a |
| Cash & equivalents | $8.52B | $10.21B | $5.23B | $7.27B |
| Total assets | $86.71B | $90.04B | $133.96B | $112.48B |
| Total liabilities | n/a | $71.53B | n/a | n/a |
| Shareholders' equity | $52.13B | $18.47B | -$3.27B | $26.54B |
| Return on year-end equity | 12.5% | 38.2% | n/a | 77.8% |
| Shares outstanding | n/a | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Abbott Laboratories | Bristol Myers Squibb Co | AbbVie Inc. | Eli Lilly & Co |
|---|---|---|---|---|
| Latest | $44.33B Ended 2025-12-31 | $48.19B Ended 2025-12-31 | $61.16B Ended 2025-12-31 | $65.18B Ended 2025-12-31 |
| 1 year earlier | $41.95B Ended 2024-12-31 | $48.30B Ended 2024-12-31 | $56.33B Ended 2024-12-31 | $45.04B Ended 2024-12-31 |
| 2 years earlier | $40.11B Ended 2023-12-31 | $45.01B Ended 2023-12-31 | $54.32B Ended 2023-12-31 | $34.12B Ended 2023-12-31 |
| 3 years earlier | $43.65B Ended 2022-12-31 | $46.16B Ended 2022-12-31 | $58.05B Ended 2022-12-31 | $28.54B Ended 2022-12-31 |
| 4 years earlier | $43.08B Ended 2021-12-31 | $46.38B Ended 2021-12-31 | $56.20B Ended 2021-12-31 | $28.32B Ended 2021-12-31 |